THE-OPEN-GROUP
25.8.2020 15:02:17 CEST | Business Wire | Press release
The Open Group , the vendor-neutral technology consortium, today announced the formation of the Open Footprint™ Forum, a Forum of The Open Group. This Forum will be focused on developing open and vendor-neutral industry standards to provide consistent and accurate measurement and reporting of environmental footprint data. The initial launch will focus on greenhouse gas (GHG) emissions data. The Forum will also cover the entire physical environmental footprint to include water, waste, and land data.
“Accurate data on environmental footprint data is critical for modern enterprises – not only for mandatory government compliance reporting and meeting customer and partner demands, but also for taking action,” said Johan Krebbers, GM Digital Emerging Technologies/VP IT Innovation at Shell . “Yet organizations face significant challenges when it comes to managing their environmental footprints such as a lack of consistency, compatibility, and interoperability throughout supply chains, as well as a shortage of standards for recording and processing this type of data.”
To meet the increasing business need for transparent and uniform reporting on environmental footprint data, the Forum will collaborate on the definition, design, and delivery of Open Footprint Data Platform standards. In the case of reporting GHG emissions, accurate data on emissions, consumptions, and base calculations will enable businesses to compare the footprint of goods and services in the value chain across every industry.
Alongside these standards, the Forum will create an open source-based system which will be accessible to all organizations. This Reference Implementation will act as the foundation for organizations to harness their own Open Footprint Data Forum implementations expected to be available from multiple parties.
“There is an urgent need to transform how we manage and report on environmental footprint data,” said Steve Nunn, President and CEO of The Open Group. “By utilizing new digital technologies and drawing on a huge amount of industry expertise, we are dedicated to enhancing reliability, credibility, and accountability around environmental data reporting to benefit businesses, governments, NGOs, and society as a whole. As an increasing number of organizations join the Forum, including operators, suppliers, and academic institutions from all industries, we are set to make substantial headway in helping businesses to better measure, monitor, and report their environmental footprints through the creation of open technology standards.”
There are currently fifteen organizations from multiple industries committed as members of the Open Footprint Forum, including Accenture, BP, Chevron, Cognite, DNV GL, Emisoft, Equinor, Halliburton, Infosys, Intel, Microsoft, Schlumberger, Shell, University of Oslo, and Wipro. Working together, member organizations will take an agile approach to the development of the Open Footprint Data Platform standards.
The Open Footprint Forum is open to all organizations. Information about the Forum and membership can be found here .
-ENDS-
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 750 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005591/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
